Plasma phospholipids identify antecedent memory impairment in older adults

Nature Medicine

Volumn 20, Issue 4, 2014, Pages 415-418

  Mapstone, Mark ^a   Cheema, Amrita K ^b   Fiandaca, Massimo S ^b   Zhong, Xiaogang ^b   Mhyre, Timothy R ^b   Macarthur, Linda H ^b   Hall, William J ^a   Fisher, Susan G ^a,f   Peterson, Derick R ^a   Haley, James M ^c   Nazar, Michael D ^c   Rich, Steven A ^d   Berlau, Dan J ^e,f,g   Peltz, Carrie B ^e   Tan, Ming T ^b   Kawas, Claudia H ^e   Federoff, Howard J ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c UNITY HEALTH SYSTEM   (United States)

^d ROCHESTER GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g REGIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; DOPA; LYSINE; PHENYLALANINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PROLINE; SEROTONIN; STABLE ISOTOPE; TAURINE;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CELL MEMBRANE; COGNITION; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY;

AGED; ALZHEIMER DISEASE; ASPARAGINE; BIOLOGICAL MARKERS; CARNITINE; COHORT STUDIES; DIPEPTIDES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYSOPHOSPHATIDYLCHOLINES; MALATES; MALE; MEMORY DISORDERS; METABOLOME; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPIDS; PROLINE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPHINGOMYELINS; URSODEOXYCHOLIC ACID;

EID: 84898447902     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3466     Document Type: Article

References (40)

1. World Health Organization. Dementia: a Public Health Priority (World Health Organization, Geneva, 2012).
2. Sperling, R.A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 7, 280-292 (2011).
3. Hulstaert, F. et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562 (1999).
4. Small, S.A., Perera, G.M., De La Paz, R., Mayeux, R. & Stern, Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann. Neurol. 45, 466-472 (1999).
5. Klunk, W.E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319 (2004).
6. Franceschi, C. et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. NY Acad. Sci. 908, 244-254 (2000).
7. Thambisetty, M. & Lovestone, S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark. Med. 4, 65-79 (2010).
8. Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B Stat. Methodol. 58, 267-288 (1996).
9. Hastie, T., Tibshirani, R. & Friedman, J. The Elements of Statistical Learning; Data Mining, Inference, and Prediction. (Springer-Verlag, New York, 2008).
10. van Meer, G. & de Kroon, A.I. Lipid map of the mammalian cell. J. Cell Sci. 124, 5-8 (2011).
11. Jones, L.L., McDonald, D.A. & Borum, P.R. Acylcarnitines: role in brain. Prog. Lipid Res. 49, 61-75 (2010).
12. Nitsch, R.M. et al. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA 89, 1671-1675 (1992).
13. Schaefer, E.J. et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 63, 1545-1550 (2006).
14. Mulder, C. et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J. Neural Transm. 110, 949-955 (2003).
15. Walter, A. et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 25, 1299-1303 (2004).
16. Prasad, M.R., Lovell, M.A., Yatin, M., Dhillon, H. & Markesbery, W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23, 81-88 (1998).
17. Pettegrew, J.W., Panchalingam, K., Hamilton, R.L. & McClure, R.J. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 26, 771-782 (2001).
18. Haughey, N.J., Bandaru, V.V., Bae, M. & Mattson, M.P. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 1801, 878-886 (2010).
19. Kordower, J.H. & Fiandaca, M.S. Response of the monkey cholinergic septohippocampal system to fornix transection: a histochemical and cytochemical analysis. J. Comp. Neurol. 298, 443-457 (1990).
20. Kordower, J.H. et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc. Natl. Acad. Sci. USA 91, 10898-10902 (1994).
21. Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T. & DeLong, M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122-126 (1981).
22. Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234 (2006).
23. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144 (2010).
24. Irizarry, M.C. Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234 (2004).
25. Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13, 1359-1362 (2007).
26. Doecke, J.D. et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69, 1318-1325 (2012).
27. Roe, C.M. et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 76, 501-510 (2011).
28. Fagan, A.M. et al. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343-349 (2007).
29. Albert, M.S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279 (2011).
30. Petersen, R.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308 (1999).
31. Espinosa, A. et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J. Alzheimers Dis. 34, 769-780 (2013).
32. McKhann, G.M. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269 (2011).
33. Want, E.J. et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 5, 1005-1018 (2010).
34. Grebe, S.K. & Singh, R.J. LC-MS/MS in the clinical laboratory - where to from here? Clin. Biochem. Rev. 32, 5-31 (2011).
35. Illig, T. et al. A genome-wide perspective of genetic variation in human metabolism. Nat. Genet. 42, 137-141 (2010).
36. Römisch-Margl, W.P.C., Bogumil, R., Röhring, C. & Suhre, K. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics 7, 1-14 (2011).
37. Bolstad, B.M., Irizarry, R.A., Astrand, M. & Speed, T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).
38. Ma, S. & Huang, J. Regularized ROC method for disease classification and biomarker selection with microarray data. Bioinformatics 21, 4356-4362 (2005).
39. Liu, Z. & Tan, M. ROC-based utility function maximization for feature selection and classification with applications to high-dimensional protease data. Biometrics 64, 1155-1161 (2008).
40. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1-22 (2010).